Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


More On

Merck wins its fourth Fosamax case

Drug maker is victorious in litigation involving osteoporosis drug

Yesterday drug maker Merck & Co. won another case in which a patient claimed the company’s osteoporosis drug Fosamax caused jaw and dental injuries.

Florida resident Linda Secrest sued Merck, claiming she suffered jaw problems after taking Fosamax between 1998 and 2005 and that the company failed to provide warnings about the possibility of developing jaw and dental injuries. But yesterday, a New York federal jury found in favor of Merck.

The case is the fourth bellwether case to go to trial. Merck has won three of the four cases. A fifth case was dismissed prior to trial.

According to Businessweek and the Wall Street Journal, Merck is facing about 1,650 failure-to-warn cases in federal and state court alleging that Fosamax causes a jaw-destroying condition and that the company failed to properly warn consumers about the risk. Merck has said the condition did not occur in any clinical trials of Fosamax.

Ashley Post

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.